TASLY(SH:600535) Shang Hai Zheng Quan Bao·2025-10-24 20:20Core Viewpoint - The company, Tian Shi Li Pharmaceutical Group Co., Ltd., has released its third-quarter report for 2025, indicating a decline in revenue across its pharmaceutical industrial and commercial sectors [3][11]. Financial Performance - The company's revenue for the first nine months of 2025 decreased by 2.35% compared to the same period last year, with pharmaceutical industrial revenue down by 0.47% and pharmaceutical commercial revenue down by 16.70% [3][11]. - The financial statements for the third quarter are unaudited, and the company has confirmed the accuracy and completeness of the financial information provided [2][3]. Corporate Governance - The board of directors and senior management have guaranteed the authenticity and completeness of the quarterly report, taking legal responsibility for any misrepresentation or omissions [2][8]. - The ninth board meeting of the company was held on October 23, 2025, where the third-quarter report and organizational structure adjustments were approved unanimously by all attending members [8][9]. Organizational Changes - The company has proposed adjustments to its organizational structure to enhance operational efficiency and effectiveness in response to its development needs [8].